Trial Profile
A Randomised, Open-label Four-way Crossover Study to Evaluate Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Single Dose (7.5 μg Tiotropium, 25 μg Salmeterol, Inhalation Powder, Hard Capsule, HandiHaler2), a Free Combined Single Dose of 18 μg Tiotropium [Spiriva HandiHaler] and 50 μg Salmeterol [Serevent Diskus], a Single Dose of 50μg Salmeterol (Serevent Diskus) and a Single Dose of 18 μg Tiotropium (Spiriva HandiHaler) in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Salmeterol/tiotropium bromide (Primary) ; Salmeterol; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 09 Oct 2014 New trial record